A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys

Transplantation

Volumn 84, Issue 8, 2007, Pages 1020-1028

  Imai, Atsushi ^a   Suzuki, Tomomi ^a   Sugitani, Atsushi ^b   Itoh, Tomoo ^c   Ueki, Shinya ^a   Aoyagi, Takeshi ^a   Yamashita, Kenichiro ^a   Taniguchi, Masahiko ^a   Takahashi, Nobuaki ^d   Miura, Toru ^d   Shimamura, Tsuyoshi ^a   Furukawa, Hiroyuki ^a   Todo, Satoru ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Anti CD40 monoclonal antibody; Costimulatory pathway; Kidney transplantation; Nonhuman primates

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; DRUG ANTIBODY; MONOCLONAL ANTIBODY 4D11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BIOCHEMISTRY; BLOOD CELL COUNT; BRAIN INFARCTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; GRAFT SURVIVAL; HISTOLOGY; HYDRONEPHROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MONKEY; NONHUMAN; PHENOTYPE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LIVING DONORS; MACACA FASCICULARIS;

EID: 37349029002     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000286058.79448.c7     Document Type: Article

References (50)

1. Nomura M, Yamashita K, Murakami M, et al. Induction of donor-specific tolerance by adenovirus-mediated CD40Ig gene therapy in rat liver transplantation. Transplantation 2002; 73: 1403.
2. Yamashita K, Masunaga T, Yanagida N, et al. Long-term acceptance of rat cardiac allografts on the basis of adenovirus mediated CD40Ig plus CTLA4Ig gene therapies. Transplantation 2003; 76: 1089.
3. Hua N, Yamashita K, Hashimoto T, et al. Gene therapy-mediated CD40L and CD28 co-stimulatory signaling blockade plus transient anti-xenograft antibody suppression induces long-term acceptance of cardiac xenografts. Transplantation 2004; 78: 1463.
4. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61: 4.
5. Sho M, Sandner SE, Najafian N, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002; 236: 667.
6. Barnhart B, Ford GS, Bhushan A, et al. A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions. Immunology 2000; 99: 54.
7. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
8. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94: 8789.
9. Preston EH, Xu H, Dhanireddy KK, et al. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant 2005; 5: 1032.
10. Kanmaz T, Fechner JJ, Jr., Torrealba J, et al. Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004; 77: 914.
11. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
12. Schuler W, Bigaud M, Brinkmann V, et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004; 77: 717.
13. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin- dependent mechanism. Nat Med 2002; 8: 247.
14. Inwald DP, McDowall A, Peters MJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041.
15. Koyama I, Kawai T, Andrews D, et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004; 77: 460.
16. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant 2002; 2: 898.
17. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876.
18. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003; 75: 637.
19. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74: 933.
20. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174: 542.
21. Ishida I, Tomizuka K, Yoshida H, et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4: 91.
22. van der Pol W, van de Winkel JG. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998; 48: 222.
23. Miura T, Okimura K, Takahashi N, et al. Pharamacological and Toxicological studies of a fully human antibody (4D11) against human CD40 in human samples in vitro and non-human primates in vivo. Am J Transplant 2005; 5: 420.
24. Lobashevsky A, Smith JP, Kasten-Jolly J, et al. Identification of DRB alleles in rhesus monkeys using polymerase chain reaction-sequence-specific primers (PCR-SSP) amplification. Tissue Antigens 1999; 54: 254.
25. Todo S, Ueda Y, Demetris JA, et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery 1988; 104: 239.
26. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
27. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349.
28. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
29. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997; 9: 641.
30. Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003; 196: 85.
31. Ritter G, Cohen LS, Williams C, Jr., et al. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001; 61: 6851.
32. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111.
33. Haanstra KG, Sick EA, Ringers J, et al. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation 2005; 79: 1623.
34. Xu H, Tadaki DK, Elster EA, et al. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation 2002; 74: 940.
35. Ossevoort MA, Ringers J, Kuhn EM, et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 1999; 68: 1010.
36. Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001; 72: 377.
37. Montgomery SP, Xu H, Tadaki DK, et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in non-human primate renal transplantation. Transplantation 2002; 74: 1365.
38. Knechtle SJ, Pirsch JD, Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
39. Knechtle SJ, Fechner JH, Jr., Dong Y, et al. Primate renal transplants using immunotoxin. Surgery 1998; 124: 438.
40. Torrealba JR, Fernandez LA, Kanmaz T, et al. Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection. Transplantation 2003; 76: 524.
41. Jones ND, Van Maurik A, Hara M, et al. CD40-CD40 ligand-independent activation of CD8 T cells can trigger allograft rejection. J Immunol 2000; 165: 1111.
42. Raisky O, Spriewald BM, Morrison KJ, et al. CD8(+) T cells induce graft vascular occlusion in a CD40 knockout donor/recipient combination. J Heart Lung Transplant 2003; 22: 177.
43. Grimm PC, McKenna R, Nickerson P, et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999; 10: 1582.
44. Kawabe T, Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity 1994; 1: 167.
45. de Vos AF, Melief MJ, van Riel D, et al. Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys. Eur J Immunol 2004; 34: 3446.
46. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999; 17: 399.
47. Wolniak KL, Shinall SM, Waldschmidt TJ. The germinal center response. Crit Rev Immunol 2004; 24: 39.
48. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
49. Cho CS, Burkly LC, Fechner JH, Jr., et al. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients. Transplantation 2001; 72: 587.
50. Xu H, Elster EA, Blair PJ, et al. Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. Am J Transplant 2003; 3: 1350.